CAS: 107650-22-6; Methyl 6-Bromo-4-Indolecarboxylate

相似化合物

898746-91-3 882679-96-1 1440807-02-2

2-甲基-3-硝基苯甲酸置于1,3-二溴-5,5-二甲基海因,硫酸体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 14.0H,反应生成6-溴-4-吲哚甲酸甲酯
参考文献: Selective Inhibitors Of Clinically Important Mutants Of The Egfr Tyrosine Kinase[fr] Inhibiteurs Sélectifs De Mutants Cliniquement Importants De La Tyrosine Kinase De L'Egfr
标题: Selective Inhibitors Of Clinically Important Mutants Of The Egfr Tyrosine Kinase[fr] Inhibiteurs Sélectifs De Mutants Cliniquement Importants De La Tyrosine Kinase De L'Egfr
摘要:本发明提供了式(i)的化合物或其亚类结构或种属,或其药学上可接受的盐,酯,溶剂化合物和/或前药,以及用于治疗或改善异常细胞增殖性疾病,如癌症的方法和组合物,其中a,R2,R3,R10,E1,E2,E3,Y和z如本文所定义.

专利信息

专利号:US-2023025807-A1
优先权日:2019-10-30
标题:Cd38 inhibitors
发明人：KULKARNI SANTOSH S; LAGU BHARAT; WU XINYUAN
权利人:MITOBRIDGE INC
摘要:The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD + or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).